NasdaqGS:BIIBBiotechs
How Class Action Risks and Lupus Drug Advances Could Reframe Biogen's (BIIB) Innovation Narrative
Biogen recently saw a federal securities class action certified for investors who acquired its shares between June 8, 2021 and July 12, 2021, while also highlighting investigational therapies such as litifilimab for cutaneous lupus erythematosus and salanersen for spinal muscular atrophy at major medical meetings.
Together, the class action certification and progress in autoimmune and neuromuscular drug pipelines underscore how Biogen’s legal exposure and innovation efforts are evolving in...